ASND vs LKFT
Ascendis Pharma A/S and Lakefront Biotherapeutics NV, side by side — 10 fiscal years reported in EUR, drawn from SEC filings.
Most recent reported year
| Metric | ASND | LKFT |
|---|---|---|
| Revenue | €720.1M | €1.1B |
| Net income | €-228.0M | €320.9M |
| Gross margin | 86.8% | 97.3% |
| Net margin | −31.7% | 28.9% |
| Return on equity | · | 10.5% |
| Diluted EPS | −€3.76 | €4.87 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | · | €-271.2M |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | 1.04× | 20.15× |
| Revenue CAGR 5y | 153.0% | 18.4% |
| Profit CAGR 5y | · | · |
LKFT bills 1.5× the revenue of ASND, and ASND closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ASND | LKFT |
|---|---|---|
| FY2025 | €720.1M | €1.1B |
| FY2024 | €363.6M | €275.6M |
| FY2023 | €266.7M | €239.7M |
| FY2022 | €51.2M | €241.2M |
| FY2021 | €7.8M | €234.4M |
| FY2020 | €7.0M | €478.1M |
| FY2019 | €13.4M | €834.9M |
| FY2018 | €10.6M | €278.7M |
| FY2017 | €1.5M | €127.1M |
| FY2016 | €4.6M | €129.5M |
Bottom line
| Fiscal year | ASND | LKFT |
|---|---|---|
| FY2025 | €-228.0M | €320.9M |
| FY2024 | €-378.1M | €74.1M |
| FY2023 | €-481.4M | €211.7M |
| FY2022 | €-583.2M | €-218.0M |
| FY2021 | €-383.6M | €-103.2M |
| FY2020 | €-419.0M | €-305.4M |
| FY2019 | €-218.0M | €149.8M |
| FY2018 | €-130.1M | €-29.3M |
| FY2017 | €-123.9M | €-115.7M |
| FY2016 | €-68.5M | €54.0M |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −€392,116,000 | LKFT |
| FY2024 | +€87,992,000 | ASND |
| FY2023 | +€26,994,000 | ASND |
| FY2022 | −€190,075,000 | LKFT |
| FY2021 | −€226,606,000 | LKFT |
| FY2020 | −€471,100,000 | LKFT |
| FY2019 | −€821,526,000 | LKFT |
| FY2018 | −€268,085,000 | LKFT |
| FY2017 | −€125,557,000 | LKFT |
| FY2016 | −€124,913,000 | LKFT |
| FY2015 | −€31,445,000 | LKFT |
The higher-revenue side has changed between ASND and LKFT over this period. The gap has widened since the earliest year compared.
11 of 11 comparable fiscal years — a year missing data on either side is not counted.
6 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −60.5 pp | LKFT |
| FY2024 | −130.8 pp | LKFT |
| FY2023 | −268.8 pp | LKFT |
| FY2022 | −1049.3 pp | LKFT |
| FY2018 | −1219.0 pp | LKFT |
| FY2015 | −106.2 pp | LKFT |
LKFT has kept the higher net margin in every one of these 6 fiscal years.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's net margin has been more volatile than LKFT's over the 6 comparable fiscal years — 487.7 percentage points of standard deviation against 126.7.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
LKFT led in net margin in every one of the 6 comparable fiscal years — a structural lead, not a recent swing.
6 of 11 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ASND's return on equity has been more volatile than LKFT's over the 8 comparable fiscal years — 20.4 percentage points of standard deviation against 12.3.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ASND and LKFT over these 8 fiscal years — ASND led in 1 and LKFT in 7.
8 of 11 comparable fiscal years — a year missing data on either side is not counted.